{
    "clinical_study": {
        "@rank": "40353", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo given for 5 days (qd po)"
            }, 
            {
                "arm_group_label": "Icariin - 100 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Icariin given at 100 mg/day (qd po) for 5 days"
            }, 
            {
                "arm_group_label": "Icariin - 200 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Icariin given at 200 mg/day (qd po) for 5 days"
            }, 
            {
                "arm_group_label": "Icariin - 300 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Icariin given at 300 mg/day (qd po) for 5 days"
            }, 
            {
                "arm_group_label": "Icariin - 400 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Icariin given at 400 mg/day (qd po) for 5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the pharmacokinetic properties of icariin, an\n      active ingredient in the over-the-counter supplement, Horny Goat Weed."
        }, 
        "brief_title": "Icariin to Prevent Corticosteroid-related Memory Changes", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "the Pharmacokinetic Profile of Icariin in Humans", 
        "detailed_description": {
            "textblock": "The purpose of this study is to investigate the pharmacokinetic properties of icariin, an\n      active ingredient in the over-the-counter supplement, Horny Goat Weed.\n\n      Healthy volunteers will be randomly assigned to a 5 day course of icariin at 100 mg/day, 200\n      mg/day, 300 mg/day, or 400 mg/day, or a matching placebo.\n\n      24 hours of blood samples will be drawn for pharmacokinetic analysis.  Side effects will be\n      assessed for the full 5 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy men and women\n\n          -  Ages 18 - 50 years\n\n          -  BMI between 18.5 and 30\n\n          -  Ability to read and speak English\n\n        Exclusion Criteria:\n\n          -  Medication changes in the past 30 days\n\n          -  Current or past 30 days opioid therapy\n\n          -  Current or past 30 days erectile dysfunction therapy\n\n          -  Significant medical conditions\n\n          -  History of major psychiatric illness\n\n          -  History of drug/alcohol abuse or current tobacco use\n\n          -  Vulnerable populations including pregnant or nursing women, the incarcerated, or\n             individuals with severe cognitive disorders\n\n          -  History of allergic reaction or contraindication to icariin\n\n          -  Baseline QIDS score > 7, current suicidal ideation, or history of suicide attempt\n\n          -  Clinically significant abnormalities on baseline labs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112123", 
            "org_study_id": "102012-052", 
            "secondary_id": "1R21AT007869-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Icariin - 100 mg/day", 
                    "Icariin - 200 mg/day", 
                    "Icariin - 300 mg/day", 
                    "Icariin - 400 mg/day"
                ], 
                "intervention_name": "Icariin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Horny Goat Weed", 
                    "epimedium extract"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Matching placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "icariin", 
            "pharmacokinetics", 
            "healthy participants"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "kimberlyk.anderson@utsouthwestern.edu", 
                "last_name": "Kimberly K Anderson, BS", 
                "phone": "214-645-6954"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "UT Southwestern Medical Center"
            }, 
            "investigator": {
                "last_name": "E. Sherwood Brown, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Icariin to Prevent Corticosteroid-related Memory Changes", 
        "overall_contact": {
            "email": "kimberlyk.anderson@utsouthwestern.edu", 
            "last_name": "Kimberly K Anderson, BS", 
            "phone": "214-645-6954"
        }, 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "E. Sherwood Brown, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Blood concentration levels of icariin", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112123"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Texas Southwestern Medical Center", 
            "investigator_full_name": "Sherwood Brown", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Arizona Sexual Experiences Scale for measuring side effects relating to sexual functioning.", 
                "measure": "A-SEX", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }, 
            {
                "description": "Systematic Assessment for Treatment Emergent Events - to assess general side effects", 
                "measure": "SAFTEE", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }, 
            {
                "description": "Prothrombin time/Partial thromboplastin time", 
                "measure": "PT/PTT levels", 
                "safety_issue": "Yes", 
                "time_frame": "5 days"
            }
        ], 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Center for Complementary and Alternative Medicine (NCCAM)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}